Evolution of COVID-19 in Anticoagulated or Antiaggregated Patients (CORONA Study)

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Status: Completed

Conditions: Covid19

Treatments: Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Study type: Observational

Funder types: Other

Identifiers

NCT04518735

IIBSP-COV-2020-24

Details and patient eligibility

About

CORONA is a retrospective, observational, one center study to investigate the clinical evolution (in terms of survival and thromboembolic complications) of patients on chronic treatment with anticoagulants or antiplatelet agents who are admitted to the hospital for COVID-19 compared with patients who do not receive anticoagulants or antiplatelet agents.

Enrollment: 1,707 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient admitted for COVID-19 at the Hospital de la Santa Creu i Sant Pau,
• Positive COVID-19 polymerase chain reaction test
• Length of stay more than 24 hours

Exclusion criteria

• No objective diagnose for COVID-19
• Outpatient
• Lenght of stay less than 24hours

Trial design

1,707 participants in 3 patient groups

Patients on previous oral anticoagulant treatment

Description:

Patients receiving chronic anticoagulation with vitamin K antagonists (VKA, warfarin or acenocumarol) or with DOACs (dabigatran, rivaroxaban, apixaban or edoxaban) for any indication

Treatment:

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Patients on previous antiplatelet therapy

Description:

Patients receiving chronic antiplatelet therapy (aspirin, clopidogrel, prasugrel, ticagrelor, cangrelor, dipyridamol) for any indication

Treatment:

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19

Patients without antithrombotic therapy

Description:

Patients receiving nor chronic oral anticoagulation neither chronic antiplatelet therapy

Treatment:

Other: Antithrombotic Therapy (anticoagulant and/or antiplatelet) before admission for Covid19